Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles

Open access
Underwood, Benjamin R., Broadhurst, David, Dunn, Warwick B., Ellis, David I., Michell, Andrew W., Vacher, Coralie, Mosedale, David E., Kell, Douglas B., Barker, Roger A., Grainger, David J., Rubinsztein, David C. · 2006 · Brain

Abstract

There has been considerable progress recently towards developing therapeutic strategies for Huntington's disease (HD), with several compounds showing beneficial effects in transgenic mouse models. However, human trials in HD are difficult, costly and time-consuming due to the slow disease course, insidious onset and patient-to-patient variability. Identification of molecular biomarkers associated with disease progression will aid the development of effective therapies by allowing further validation of animal models and by providing hopefully more sensitive measures of disease progression. Here, we apply metabolic profiling by gas chromatography-time-of-flight-mass spectrometry to serum samples from human HD patients and a transgenic mouse model in a hypothesis-generating search for disease biomarkers. We observed clear differences in metabolic profiles between transgenic mice and wild-type littermates, with a trend for similar differences in human patients and control subjects. Thus, the metabolites responsible for distinguishing transgenic mice also comprised a metabolic signature tentatively associated with the human disease. The candidate biomarkers composing this HD-associated metabolic signature in mouse and humans are indicative of a change to a pro-catabolic phenotype in early HD preceding symptom onset, with changes in various markers of fatty acid breakdown (including glycerol and malonate) and also in certain aliphatic amino acids. Our data raise the prospect of a robust molecular definition of progression of HD prior to symptom onset, and if validated in a genuinely prospective fashion these biomarker trajectories could facilitate the development of useful therapies for this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awl027

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 183

Metadata

Authors
Underwood, B. R., Broadhurst, D., Dunn, W. B., Ellis, D. I., Michell, A. W., Vacher, C., Mosedale, D. E., Kell, D. B., Barker, R. A., Grainger, D. J., & Rubinsztein, D. C.
Venue
Brain
Published
2006-02-07
Volume
129
Issue
4
Pages
877-886
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2145196491
Cited by
183
References
6
FWCI
6.94
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. https://app.cochat.ai/papers/10.1093/brain/awl027
The paper
Underwood, B. R., Broadhurst, D., Dunn, W. B., Ellis, D. I., Michell, A. W., Vacher, C., Mosedale, D. E., Kell, D. B., Barker, R. A., Grainger, D. J., & Rubinsztein, D. C. (2006). Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain. https://doi.org/10.1093/brain/awl027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.